Cessation of imatinib mesylate may lead to sustained hematologic and mole remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome

被引：20

作者：

Helbig, Grzegorz ^{[1
]}

Kyrcz-Krzemien, Slawomira ^{[1
]}

机构：

[1] Silesian Med Univ, Dept Hematol & Bone Marrow Transplantat, Katowice, Poland

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2014年 / 89卷 / 01期

关键词：

CHRONIC EOSINOPHILIC LEUKEMIA; COMPLETE MOLECULAR REMISSION; DISCONTINUATION; EFFICACY;

D O I：

10.1002/ajh.23588

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：115 / 115

页数：1

共 8 条

[1] The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study [J].

Baccarani, Michele ;

Cilloni, Daniela ;

Rondoni, Michela ;

Ottaviani, Emanuela ;

Messa, Francesca ;

Merante, Serena ;

Tiribelli, Mario ;

Buccisano, Francesco ;

Testoni, Nicoletta ;

Gottardi, Enrico ;

de Vivo, Antonio ;

Giugliano, Emilia ;

Iacobucci, Ilaria ;

Paolini, Stefania ;

Soverini, Simona ;

Rosti, Gianantonio ;

Rancati, Francesca ;

Astolfi, Cinzia ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Martinelli, Giovanni .

HAEMATOLOGICA, 2007, 92 (09) :1173-1179

[2] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].

Cools, J ;

DeAngelo, DJ ;

Gotlib, J ;

Stover, EH ;

Legare, RD ;

Cortes, J ;

Kutok, J ;

Clark, J ;

Galinsky, I ;

Griffin, JD ;

Cross, NCP ;

Tefferi, A ;

Malone, J ;

Alam, R ;

Schrier, SL ;

Schmid, J ;

Rose, M ;

Vandenberghe, P ;

Verhoef, G ;

Boogaerts, M ;

Wlodarska, I ;

Kantarjian, H ;

Marynen, P ;

Coutre, SE ;

Stone, R ;

Gilliland, DG .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214

[3] Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia [J].

Helbig, Grzegorz ;

Moskwa, Andrzej ;

Hus, Marek ;

Piszcz, Jaroslaw ;

Swiderska, Alina ;

Urbanowicz, Alina ;

Calbecka, Malgorzata ;

Seferynska, Ilona ;

Razny, Malgorzata ;

Rodzaj, Marek ;

Zuk, Ewa ;

Kyrcz-Krzemien, Slawomira .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) :967-969

[4] Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia [J].

Jovanovic, Jelena V. ;

Score, Joannah ;

Waghorn, Katherine ;

Cilloni, Daniela ;

Gottardi, Enrico ;

Metzgeroth, Georgia ;

Erben, Philipp ;

Popp, Helena ;

Walz, Christoph ;

Hochhaus, Andreas ;

Roche-Lestienne, Catherine ;

Preudhomme, Claude ;

Solomon, Ellen ;

Apperley, Jane ;

Rondoni, Michela ;

Ottaviani, Emanuela ;

Martinelli, Giovanni ;

Brito-Babapulle, Finella ;

Saglio, Giuseppe ;

Hehlmann, Ruediger ;

Cross, Nicholas C. P. ;

Reiter, Andreas ;

Grimwade, David .

BLOOD, 2007, 109 (11) :4635-4640

[5] Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia:: implications for optimal dosing [J].

Klion, Amy D. ;

Robyn, Jamie ;

Maric, Irina ;

Fu, Weiming ;

Schmid, Laura ;

Lemery, Steven ;

Noel, Pierre ;

Law, Melissa A. ;

Hartsell, Marilyn ;

Talar-Williams, Cheryl ;

Fay, Michael P. ;

Dunbar, Cynthia E. ;

Nutman, Thomas B. .

BLOOD, 2007, 110 (10) :3552-3556

[6] Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial [J].

Mahon, Francois-Xavier ;

Rea, Delphine ;

Guilhot, Joelle ;

Guilhot, Francois ;

Huguet, Francoise ;

Nicolini, Franck ;

Legros, Laurence ;

Charbonnier, Aude ;

Guerci, Agnes ;

Varet, Bruno ;

Etienne, Gabriel ;

Reiffers, Josy ;

Rousselot, Philippe .

LANCET ONCOLOGY, 2010, 11 (11) :1029-1035

[7] Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome [J].

Pardanani, A. ;

D'Souza, A. ;

Knudson, R. A. ;

Hanson, C. A. ;

Ketterling, R. P. ;

Tefferi, A. .

LEUKEMIA, 2012, 26 (11) :2439-2441

[8] Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study [J].

Ross, David M. ;

Branford, Susan ;

Seymour, John F. ;

Schwarer, Anthony P. ;

Arthur, Christopher ;

Yeung, David T. ;

Phuong Dang ;

Goyne, Jarrad M. ;

Slader, Cassandra ;

Filshie, Robin J. ;

Mills, Anthony K. ;

Melo, Junia V. ;

White, Deborah L. ;

Grigg, Andrew P. ;

Hughes, Timothy P. .

BLOOD, 2013, 122 (04) :515-522

← 1 →